Company Overview - Gentex Corporation, founded in 1974, is a leading supplier in various sectors including digital vision, connected car technologies, dimmable glass, fire protection technologies, medical devices, and consumer electronics [2] Dividend Announcement - The Board of Directors of Gentex Corporation declared a quarterly cash dividend of $0.12 per share, which will be payable on October 22, 2025 [1] - Shareholders of record will be those holding common stock at the close of business on October 8, 2025 [1]

Core Insights - Nuvini Group Limited has announced the promotion of Gustavo Usero to Chief Operating Officer, effective September 1, 2025, reflecting his significant contributions to the company [1][2]. Company Overview - Nuvini is a leading technology conglomerate in the Latin American SaaS sector, headquartered in São Paulo, Brazil [4]. - The company focuses on acquiring profitable, high-growth B2B SaaS businesses with strong recurring revenue and cash flow generation [4]. - Nuvini aims to foster an entrepreneurial environment to enable its portfolio companies to scale and maintain industry leadership [4]. Leadership and Strategy - Gustavo Usero, previously the Group Operating Director, has been instrumental in enhancing operational excellence, financial performance, and strategic execution across Nuvini's portfolio [2]. - His efforts include strengthening budgeting discipline, improving EBITDA margins, and driving AI adoption through global tech partnerships [2]. - Usero's promotion to COO is expected to guide Nuvini's next phase of growth, particularly in expanding operations across Latin America [3].

Core Viewpoint - SharpLink Gaming, Inc. has announced a stock repurchase program of up to $1.5 billion to enhance market support and optimize capital allocation [1][2]. Company Overview - SharpLink Gaming, Inc. is one of the largest corporate holders of Ether (ETH) and advocates for Ethereum adoption, aligning its treasury strategy with digital capital [1][3]. - The company is headquartered in Minneapolis, Minnesota, and is publicly traded on Nasdaq under the ticker SBET [3]. Stock Repurchase Program - The stock buyback program is intended to provide flexibility for the company to act decisively when its stock trades at or below the net asset value of its ETH holdings [2]. - Repurchases may occur through open market purchases, privately negotiated transactions, or other means permitted under applicable securities laws, depending on market conditions [2]. - The company is not obligated to repurchase a specific number of shares, and the program may be suspended or discontinued at any time [2]. Strategic Vision - SharpLink is focused on reimagining the future of online gaming by building scalable, secure, and transparent solutions that innovate the user experience [4].

LOS ANGELES, Aug. 22, 2025 (GLOBE NEWSWIRE) -- Xos, Inc., a leading manufacturer of medium‑duty electric vehicles and mobile charging solutions, today announced that John F Smith has been appointed to the Company’s Board of Directors, effective August 18, 2025. With Mr. Smith’s appointment, the Board has increased from eight to nine directors. Mr. Smith has been designated a Class I director and will serve until Xos’s 2028 annual meeting of stockholders and until his successor is duly elected and qualified, ...

TORONTO, Aug. 22, 2025 (GLOBE NEWSWIRE) -- New Horizon Aircraft (NASDAQ: HOVR), doing business as Horizon Aircraft (“Horizon” or the “Company”), an advanced aerospace engineering company and developer of one of the world’s first hybrid electric Vertical Take-Off and Landing (VTOL) aircraft, today provided its business update and financial results for the fourth quarter and year ended May 31, 2025. Highlights include the following: One of the world’s first ever successful fan-in-wing forward transition fligh ...

Core Viewpoint - Incannex Healthcare Inc. has announced a share repurchase program for up to $20 million of its outstanding common stock, reflecting confidence in its clinical pipeline and market valuation [1][3]. Summary by Sections Share Repurchase Program - The program allows the company to repurchase shares through various methods, including open market purchases and privately negotiated transactions, in compliance with applicable securities laws [2]. - The timing and amount of repurchases will depend on market conditions and available capital resources [2]. Company Leadership Commentary - CEO Joel Latham stated that the repurchase program demonstrates confidence in the company's pipeline and strategy, and aims to enhance long-term shareholder value [3]. - The initiative is part of a broader commitment to sustainable shareholder value and disciplined capital allocation [3]. Company Overview - Incannex is focused on developing combination medicines for chronic conditions such as obstructive sleep apnea, rheumatoid arthritis, and generalized anxiety disorder [4]. - The lead clinical program, IHL-42X, targets obstructive sleep apnea and is an oral fixed-dose combination of dronabinol and acetazolamide [4]. - Other clinical-stage candidates include IHL-675A for inflammatory conditions and PSX-001 for generalized anxiety disorder, both of which are in Phase 2 development [4].

PHILADELPHIA, Aug. 22, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in autoimmune disease and cancer, today announced that Brent Pfeiffenberger, Pharm.D., Chief Executive Officer of Century Therapeutics, will share a company presentation at the H.C. Wainwright 27th Annual Global Investment Conference. In addition, members of management will be available for meetings wi ...

Company Overview - Repligen Corporation is a global life sciences company focused on developing and commercializing innovative bioprocessing technologies and systems that enhance the manufacturing efficiency of biological drugs [3] - The company serves primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide, with a focus on areas such as Filtration and Fluid Management, Chromatography, Process Analytics, and Proteins [3] - Repligen's corporate headquarters is located in Waltham, Massachusetts, with manufacturing sites in the U.S. and additional key locations in Estonia, France, Germany, Ireland, the Netherlands, and Sweden [3] Upcoming Investor Conferences - Repligen will attend the Wells Fargo Healthcare Conference from September 3 to 5 in Boston, where CEO Olivier Loeillot will participate in an analyst-led discussion on September 4 at 8:00 a.m. ET [4] - The company will also participate in the Deutsche Bank Healthcare Summit on September 10 and 11 in New York, with CFO Jason Garland engaging in 1x1 meetings on September 10 [4] - Additionally, Repligen will be present at the Bank of America Global Healthcare Conference from September 23 to 25 in London, where CEO Olivier Loeillot will take part in an analyst-led discussion on September 25 at 6:35 a.m. ET / 11:35 a.m. British Summer Time [4] Investor Relations - A live webcast of the conference presentations will be available on Repligen's Investor Relations website, with a replay accessible for a limited time after the events [2]

COLUMBUS, Ohio, Aug. 22, 2025 (GLOBE NEWSWIRE) -- Bread Financial Holdings, Inc. (NYSE: BFH) (“Bread Financial” or the “Company”) announced that its previously announced cash tender offers (the “Tender Offers”) described in the Offer to Purchase, dated July 24, 2025 (as amended, the “Offer to Purchase”) expired at 5:00 p.m., New York City time, on August 21, 2025 (the “Expiration Date”). The following table sets forth the total aggregate principal amount of the Company’s 9.750% Senior Notes due 2029 (the “2 ...

TORONTO, Aug. 22, 2025 (GLOBE NEWSWIRE) -- BULGOLD Inc. (TSXV: ZLTO) (the “Company” or “BULGOLD”) is pleased to announce that it has filed its unaudited condensed interim financial statements and MD&A for the second quarter ended June 30, 2025. For the 3 and 6 months ending June 30, 2025, the company incurred a net comprehensive loss of $114,537 ($0.00 per share) and $152,428 ($0.01 per share) respectively. On June 30, 2025, the company had cash (and cash equivalents) of $255,401. About BULGOLD Inc. BULGOL ...